Yifan Pharmaceuticals: Ryzneuta's commercialization rights in Italy and Poland licensed to Molteni Farmaceutici.

On April 16th, Yifan Pharmaceuticals announced that its controlling subsidiary Yili Biological has signed a licensing agreement with L. Molteni & C. dei F.lli Alitti Societ di Esercizio S.p.A., granting the company exclusive development and commercialization rights for its independently developed innovative biopharmaceutical Ryzneuta in Italy and Poland. With this, Yilishu has now achieved commercialization agreement signings in 17 countries/regions in Europe.